株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

糖尿病性胃アトニー : パイプライン製品の分析

Diabetic Gastroparesis - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229780
出版日 ページ情報 英文 63 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
糖尿病性胃アトニー : パイプライン製品の分析 Diabetic Gastroparesis - Pipeline Review, H2 2016
出版日: 2016年08月31日 ページ情報: 英文 63 Pages
概要

胃アトニーとは、糖尿病の長期的な合併症の一つで、胃の消化機能に悪影響を及ぼします。高血糖が持続的に続くことにより、人体各所の神経、特に迷走神経(消化時の胃の収縮活動を制御する神経)が侵されます。発症すると、痙攣や腹痛、少し食べただけでも満腹感を感じる、吐き気・嘔吐、胃逆流、胸焼け、膨満感といった症状が生じます。さらには、食欲不振や栄養摂取量の減少も生じ、それが体重減少や栄養失調につながります。

当レポートでは、世界各国での糖尿病性胃アトニー治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

糖尿病性胃アトニーの概要

治療薬の開発

  • 糖尿病性胃アトニー向けパイプライン製品:概要
  • 糖尿病性胃アトニー向けパイプライン製品:比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で開発中の製品

糖尿病性胃アトニー治療薬の開発に従事している企業

  • Cempra Inc
  • Evoke Pharma, Inc.
  • GlaxoSmithKline Plc
  • Motus Therapeutics Inc
  • Shire Plc
  • Theravance Biopharma, Inc.

糖尿病性胃アトニー:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

糖尿病性胃アトニー治療薬:開発が休止状態の製品

糖尿病性胃アトニー治療薬:開発が中止された製品

糖尿病性胃アトニー関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8407IDB

Summary

Global Markets Direct's, 'Diabetic Gastroparesis - Pipeline Review, H2 2016', provides an overview of the Diabetic Gastroparesis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Gastroparesis
  • The report reviews pipeline therapeutics for Diabetic Gastroparesis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Gastroparesis therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Gastroparesis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Gastroparesis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Gastroparesis Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Gastroparesis - Overview
    • Pipeline Products for Diabetic Gastroparesis - Comparative Analysis
  • Diabetic Gastroparesis - Therapeutics under Development by Companies
  • Diabetic Gastroparesis - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Gastroparesis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Diabetic Gastroparesis - Products under Development by Companies
  • Diabetic Gastroparesis - Products under Investigation by Universities/Institutes
  • Diabetic Gastroparesis - Companies Involved in Therapeutics Development
    • Cempra Inc
    • Evoke Pharma, Inc.
    • GlaxoSmithKline Plc
    • Motus Therapeutics Inc
    • Shire Plc
    • Theravance Biopharma, Inc.
  • Diabetic Gastroparesis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • camicinal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEM-031 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETX-301 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metoclopramide hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • prucalopride succinate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relamorelin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate nNOS for Diabetic Gastroparesis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • velusetrag hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Diabetic Gastroparesis - Dormant Projects
  • Diabetic Gastroparesis - Discontinued Products
  • Diabetic Gastroparesis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 26, 2016: Evoke Pharma Receives Conditional FDA Acceptance of Proposed Brand Name for EVK-001
      • Jul 18, 2016: Evoke Pharma Reports Topline Results from EVK-001 Phase 3 Clinical Trial
      • Jul 07, 2016: Evoke Advances Commercial Preparations for EVK-001 with inVentiv Agreement
      • Jun 01, 2016: Evoke Completes Phase 3 Clinical Trial of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
      • May 24, 2016: Evoke Pharma Presents Data from Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
      • May 19, 2016: Evoke Enters Exclusive Commercial Supply Agreement for Active Pharmaceutical Ingredient in EVK-001
      • May 03, 2016: Evoke Announces Timing of Phase 3 Results from its Recently Fully Enrolled Pivotal Clinical Trial of EVK-001
      • Apr 25, 2016: Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis
      • Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
      • Mar 03, 2016: Evoke Accelerates New Drug Application Process by Engaging Regulatory Experts
      • Mar 01, 2016: Evoke Nears Completion of Phase 3 Clinical Trial Enrollment and Secures Extension to Credit Facility
      • Feb 17, 2016: Evoke Pharma to Present Results From Successful Thorough ECG (TQT) Study of EVK-001 at Digestive Disease Week 2016
      • Sep 28, 2015: Evoke Reaches Study Enrollment Milestone Associated With Credit Facility
      • Aug 18, 2015: Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001
      • Jun 24, 2015: Evoke Pharma Announces Publication of Clinical Data Demonstrating EVK-001 Significantly Improves Symptoms in Women With Diabetic Gastroparesis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Gastroparesis, H2 2016
  • Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Diabetic Gastroparesis - Pipeline by Cempra Inc, H2 2016
  • Diabetic Gastroparesis - Pipeline by Evoke Pharma, Inc., H2 2016
  • Diabetic Gastroparesis - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Diabetic Gastroparesis - Pipeline by Motus Therapeutics Inc, H2 2016
  • Diabetic Gastroparesis - Pipeline by Shire Plc, H2 2016
  • Diabetic Gastroparesis - Pipeline by Theravance Biopharma, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Diabetic Gastroparesis - Dormant Projects, H2 2016
  • Diabetic Gastroparesis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Diabetic Gastroparesis, H2 2016
  • Number of Products under Development for Diabetic Gastroparesis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top